scispace - formally typeset
R

Richard A. Flavell

Researcher at Yale University

Publications -  1389
Citations -  223064

Richard A. Flavell is an academic researcher from Yale University. The author has contributed to research in topics: Immune system & T cell. The author has an hindex of 231, co-authored 1328 publications receiving 205119 citations. Previous affiliations of Richard A. Flavell include National Institute for Medical Research & University of Michigan.

Papers
More filters
Journal ArticleDOI

Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells.

TL;DR: It is demonstrated here that T-cell–specific blockade of TGF-β signaling allows the generation of an immune response capable of eradicating tumors in mice challenged with live tumor cells.
Journal ArticleDOI

Interchromosomal associations between alternatively expressed loci

TL;DR: An example of eukaryotic genes located on separate chromosomes associating physically in the nucleus via interactions that may have a function in coordinating gene expression is provided and there seems to be a cell-type-specific dynamic interaction between interacting chromatin partners whereby interchromosomal interactions are apparently lost in favour of intrachromosomal ones upon gene activation.
Journal ArticleDOI

Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo

TL;DR: Monitoring the homing, expansion, and effector function of both subsets in draining and nondraining lymph nodes shows that CD8 cells expand to the same extent and produce similar levels of IFN-γ in the presence or absence of Ag-specific Treg, which abrogate CD8 T cell-mediated tumor rejection by specifically suppressing the cytotoxicity of expandedCD8 cells.
Journal ArticleDOI

Transforming Growth Factor-β Controls Development, Homeostasis, and Tolerance of T Cells by Regulatory T Cell-Dependent and -Independent Mechanisms

TL;DR: In this paper, the role of transforming growth factor-beta (TGF-beta) in inhibiting T cell functions has been studied with dominant negative TGF-β receptor transgenic models.